NCT03221881View on ClinicalTrials.gov

Neoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx®) and Paclitaxel in Breast Cancer

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

June 30, 2017

Conditions
Breast Cancer
Interventions
DRUG

Pegylated Liposomal Doxorubicin and docetaxel

Trial Locations (1)

100000

MRI, Beijing

All Listed Sponsors
lead

Hebei Medical University Fourth Hospital

OTHER

NCT03221881 - Neoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx®) and Paclitaxel in Breast Cancer | Biotech Hunter | Biotech Hunter